Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market size was valued at USD USD 1,911.3 Million in 2021, growing at a CAGR of 21.3% within the forecast period of 2022-2028. BTK is a prospective therapeutic target for different B cell malignancies and inflammatory illnesses since it is a crucial part of numerous signaling pathways that control B cell and myeloid cell proliferation, survival, and activities. Ibrutinib, Acalabrutinib, Zanubrutinib, Tirabrutinib, and Orelabrutinib are five small-molecule inhibitors that have been authorized to treat various forms of hematological malignancies and have demonstrated impressive effectiveness. Ibrutinib, a first-in-class medication, has ushered in a new era of chemotherapy-free B cell cancer treatment. Ibrutinib is so well-liked that it rose to fourth place among all cancer medications sold globally in 2021 (USD 1835.98 million in Sales). BTK inhibitors have recently been put to use in the management of inflammatory disorders. Preclinical and early-phase clinical investigations have produced promising results. The therapy of hematological malignancies and inflammatory illnesses has greatly benefited in recent years with the discovery of BTKi.
BTKi is classified into covalent or non-covalent inhibitors. Covalent bonding is the mechanism through which covalent inhibitors attach to the wild-type (WT) or mutant cysteine 481 (Cys481) residue. Using non-covalent forces like hydrogen bonds or hydrophobic interactions, non-covalent inhibitors can occupy the ATP binding pocket or a particular H3 pocket of BTK. All currently authorized medications fall within the category of irreversible covalent inhibitors, which are capable of effectively and permanently inhibiting BTK's enzyme activity. Patients taking BTKi may have undesirable side effects and acquired resistance due to off-target effects and the formation of mutations in the BTK binding sites. Pharmaceutical businesses and research institutes are creating new BTKi with greater selectivity and larger binding site coverage to overcome these challenges.
The increasing incidence of different types of Leukemia and Lymphomas can be estimated to be the most significant driving factor of the market. In 2021, Germany recorded the highest incidence of CLL (6,173 cases) followed by the United Kingdom (4,268 cases). Ibrutinib, acalabrutinib, Zanubrutinib, ibrutinib, and Orelabrutinib are five BTKi whose use in humans has been authorized. The first-generation BTKi, known as ibrutinib or PCI-32765, was identified in 2007. In monotherapy or combined therapy, it has been sporadically authorized since 2013 for the treatment of MCL, CLL/SLL, chronic graft-versus-host disease (GVHD), WM, and MZL. Additionally, increasing investments and rising initiatives to spread awareness by public and private organizations are anticipated to drive the growth of the market. Moreover, rising investment in the development of advanced technologies and an increase in the number of emerging markets. However, side effects associated with the BTK inhibitors coupled with the increasing prevalence of cardiovascular illness are the major factors hampering the growth of the market.
Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market growing at a CAGR of 21.3% within the forecast period of 2022-2028
AstraZeneca, Eli Lilly, Beigene, ONO Pharmaceutical Co., Ltd., AbbVie Inc, AstraZeneca, Janssen Global Services, LLC
Germany is the fastest-growing Country for Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market